Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Spain

European Research Council grant · Running

BiParatopic Bispecific bi-paratopic antibodies for the treatment of cancer

Coordinator
Asociacion Centro De Investigacion Cooperativa En Biociencias Cic Biogune, Spain
Runs
1 April 2025 to 30 September 2026
Status
Running
EU funding
€150k
Total cost
—
Partners
1 organisations in 1 countries
Type
European Research Council grant
Grant agreement
101213638

What the project is doing

In the project's own words, from its summary on CORDIS.

Immune checkpoint inhibitors have revolutionized cancer therapy, yet the majority of patients do not respond to current treatments, such as PD-1/PD-L1blockade. In non-small cell lung cancer (NSCLC), over 70% of patients experience immune evasion mechanisms that prevent effective immune activation. One such mechanism involves the overexpression of glycans on tumor cells, which can modulate immune responses. In this project, we propose to develop novel bispecific bi-paratopic antibodies that simultaneously target two distinct epitopes of the target.

This innovative approach is designed to provide a more comprehensive blockade of immune-suppressive functions by dual engagement of the receptor. Our bispecific antibodies will be engineered and optimized to target different epitopes, enhancing their ability to restore immune function. The project will involve the engineering, structural characterization, and functional validation of the bispecific antibodies, followed by preclinical efficacy studies in NSCLC models.

By this approach, these antibodies have the potential to overcome the limitations of existing immunotherapies, offering a new therapeutic option for cancer patients who are resistant to current treatments. In addition to the scientific development, this ERC PoC project is designed to develop a robust commercialization strategy, with the potential for patent filings and engagement with pharmaceutical partners. Our vision is to bring these bispecific antibodies to the clinic, ultimately aiming to improve outcomes for patients with NSCLC and other cancers.

Topics

Who is involved

OrganisationCityCountryRole
Asociacion Centro De Investigacion Cooperativa En Biociencias Cic BioguneDerio VizcayaSpainCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI